IL22 and neoplasm: Furthermore, CAFs promote tumor progression through the release of interleukin-1 (IL-1), IL-6, IL-22, and IL-8, of which this latter plays a crucial role in hypoxia-induced tumor apoptosis resistance and EMT remodeling [15,16,17].